RNA editing promises to go where DNA editing can’t
RNA editing is in its nascent stage, yet there are already at least 11 biotechnology companies worldwide developing RNA editing methods for a range of diseases
On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the first company to treat a genetic condition by editing RNA at the clinical level. But for all that this is a breakthrough, scientists had anticipated it.

The role of RNA in a function called RNA interference — where small RNA molecules keep a gene from being expressed — has been essential for the success of CRISPR-Cas9 gene-editing. The rapid development of mRNA vaccines during the COVID-19 pandemic exemplified the complex as well as vital role RNAs play beyond gene expression and regulation. Now, at the dawn of a new era in precision medicine, RNA editing has made a pitch to be at the forefront.